Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MORF - Morphic Holding, Inc.

IEX Last Trade
56.985
56.985   100.000%

Share volume: 0
Last Updated: Fri 16 Aug 2024 11:42:10 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 25%
Dept financing 2%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
75.57%
1 Year
89.90%
2 Year
120.81%
Key data
Stock price
$56.98
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$3.59
52 WEEK RANGE
$26.47 - $57.00
52 WEEK CHANGE
$92.01
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
50.225 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Praveen P. Tipirneni
Region: US
Website: morphictx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.

Recent news